Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 187

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 187
---
 notwithstanding our existing
marketing authorization in Israel (under which we have not yet commercialized the product). We hold exclusive rights to our proprietary
Alpha DaRT technology in our core markets, including the United States and Europe.

While local radiation therapy
has been a mainstay of cancer therapy for years, it has been mostly limited to modalities utilizing beta or gamma emissions, which primarily
destroy cells through an indirect mechanism relying on oxygen and the generation of free radicals to cause single-strand DNA breaks. By
contrast, alpha radiation has hundreds of times the linear energy transfer rate of beta-emitters. Additionally, alpha particles’
heavier mass and far shorter particle paths (less than 100 μm) relative to beta’s lighter mass and lengthier (up to 12 mm) path,
have been shown to destroy radioresistant cells in clinical studies - causing multiple, irreparable, double-strand DNA breaks and other
cellular damage upon direct impact - within a very short distance. Accordingly, we believe that alpha radiation has several significant
potential advantages for use in cancer radiotherapy, including a high relative biological efficiency (potentially enabling it to destroy
tumor cells with administration of lower levels of radiation), imperviousness to factors such as hypoxia, and a very well-defined range
of travel with limited collateral damage. Nonetheless, its use has also been limited precisely due to alpha’s extremely short particle
range in living tissue, as the range of less than 100 μm is insufficient to provide meaningful clinical utility.

The Alpha DaRT technology
employs a series of radioactive sources that are embedded with Radium-224 to enable a controlled, intratumoral release of alpha-emitting
atoms which diffuse and decay throughout the tumor, seeking to kill cancerous cells with localized precision, while penetrating deeper
into the tumor than can otherwise be reached by the limited ranges of the alpha particles themselves. Due to the inherent limited range
of the alpha particles, we believe that the Alpha DaRT technology has the potential to deliver powerful and localized precise killing
impact to the tumor without damage to surrounding healthy tissue. By combining the innate relative biological effectiveness and short
range of alpha particles in a single-use disposable form, we believe that the Alpha DaRT could address tumors that have otherwise demonstrated
poor response to radiation therapy or other standards of care, with the potential to apply to a wide range of tumors and clinical settings.

We were incorporated in Israel
in 2015 and our headquarters is located in Jerusalem, Israel.